Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis

• Published in: PloS one 2012-06, Vol.7 (6), p.e39655-e39655
• Main Authors: Chen, Min-Bin, Zhu, Ya-Qun, Xu, Jun-Ying, Wang, Li-Qiang, Liu, Chao-Ying, Ji, Zhang-Yi, Lu, Pei-Hua
• Format: Article
• Language: English
• Subjects: Adjuvant chemotherapy; Analysis; Anthracycline; Anthracyclines; Antineoplastic Agents - therapeutic use; Apoptosis; Biology; Biopsy; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Cancer; Cancer therapies; Chemotherapy; Confidence intervals; Female; Gene expression; Gene mutation; Humans; Immunohistochemistry; Medical ethics; Medical prognosis; Medical research; Medicine; Meta-analysis; Mutation; Neoadjuvant Therapy; Oncology; p53 Protein; Patients; Protein expression; Proteins; Publication Bias; Risk Factors; Studies; Treatment Outcome; Tumor proteins; Tumor suppressor genes; Tumor Suppressor Protein p53 - genetics; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0039655

Numerous studies have yielded inconclusive results regarding the relationship between tumor suppressor protein TP53 overexpression and/or TP53 gene mutations and the response to neoadjuvant chemotherapy in patients with breast cancer. The purpose of the current study was therefore to evaluate the relationship between TP53 status and response to chemotherapy in breast cancer. A total of 26 previously published eligible studies including 3,476 cases were identified and included in this meta-analysis. TP53 status (over expression of TP53 protein and/or TP53 gene mutations) was associated with good response in breast cancer patients who received neoadjuvant chemotherapy (total objective response: risk ratio [RR]= 1.20, 95% confidence interval [CI]= 1.09-1.33, p